BriaCell Therapeutics Corp BCTX 深 滬
交易中 06-25 11:12:49 美东时间
3.015
-0.015
-0.50%
華盛通- 最 高3.18
- 今 開3.11
- 成交量 4.35万股
- 最 低 2.97
- 昨 收 3.03
- 總市值 2622.99万
- 52周最高 30.00
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 2.60
- 委 比 -33.33%
- 總股本 869.98万
- 歷史最高 1860.5799
- 量 比 2.54
- 振 幅 6.93%
- 歷史最低 2.60
- 每 手 1
- 風險率 5.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMT
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has entered into a Memorandum of Understanding ("MoU"), with Uneedle, a microneedle based drug-delivery device ...
今天 19:40
BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY
BriaCell Therapeutics (NASDAQ:BCTX) reported quarterly losses of $(0.99) per share. This is a 93.96 percent increase over losses of $(16.40) per share from the same period last year.
06-10 06:08
Reported Earlier, Cancer Drug Developer BriaCell Prices $4.7M Stock Offering Of 1.45M Shares At $3.25/Share to Fund Operations and Research
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the
06-01 15:51
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Therapeutics Corp. announced the pricing of a best-efforts offering of 1,449,300 common shares at $3.25 per share, expected to raise approximately $4.7 million. Proceeds will be used for working capital, general corporate purposes, and advancing business objectives. The offering is set to close on June 2, 2026, and is being managed by ThinkEquity as the sole placement agent. The securities are being offered under a shelf registration sta...
05-31 23:59
BriaCell Therapeutics Presents Positive Clinical Data From Three Clinical Data Poster Presentations, Three Publication-Only Abstracts At 2026 ASCO Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive
05-22 19:31
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
BriaCell Therapeutics announced positive clinical data from three poster presentations and three abstracts at the 2026 ASCO Annual Meeting. Key findings include a median overall survival (OS) of 16.6 months for the Phase 3 Bria-IMT formulation, positive quality of life (QOL) data in heavily pretreated metastatic breast cancer (MBC) patients, and biomarker analyses confirming predictors of anti-cancer response. The Phase 2 study showed tolerable s...
05-22 11:30
BriaCell Therapeutics Completes Manufacturing Clinical Supplies Of Bria-PROS+ For Prostate Cancer
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed
05-14 19:39
BriaCell Therapeutics Receives FDA Clearance To Initiate Clinical Evaluation Of Bria-BRES+, Its Next Generation Cell-Based Immunotherapy For Metastatic Breast Cancer
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy
05-06 19:37
BriaCell Therapeutics Presents One Poster Featuring Data From Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor, And Two Posters Highlighting Further Analyses Of Phase 2 Data At 2026 AACR Annual Meeting
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of potential
04-20 19:34
BriaCell Therapeutics Reports Rising Losses and Funding Pressure
An announcement from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. On ...
04-01 07:35
